10:20 AM EDT, 07/23/2025 (MT Newswires) -- Philips (PHG) said Wednesday it received US Food and Drug Administration 510(k) clearance on a new version of its UroNav system, which helps doctors guide prostate cancer treatment with greater accuracy.

The updated system combines earlier magnetic resonance imaging scans with live ultrasound images during procedures, giving doctors a clearer view of the area they are treating, the company said.

Philips said that the tool helps doctors choose better treatment options and improves diagnosis, with a 30% higher detection rate of high-risk prostate cancer compared with standard methods.

The new version also includes an improved workflow that simplifies planning and reviewing procedures, making it easier for more doctors to offer less invasive treatments, according to the company.

Shares of the company were up 1.7% in recent early trading.

Price: 25.43, Change: +0.41, Percent Change: +1.66